If you made any changes in Pure these will be visible here soon.

Research Output 1997 2020

2020

Biology confirmed but biomarkers elusive in melanoma immunotherapy

Luke, J. J. & Ascierto, P. A., Jan 1 2020, (Accepted/In press) In : Nature Reviews Clinical Oncology.

Research output: Contribution to journalComment/debate

CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer

Cerbelli, B., Botticelli, A., Pisano, A., Pernazza, A., Campagna, D., De Luca, A., Ascierto, P. A., Pignataro, M. G., Pelullo, M., Rocca, C. D., Marchetti, P., Fortunato, L., Costarelli, L. & d’Amati, G., 2020, (Accepted/In press) In : Virchows Archiv.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
Lymphocytes
Drug Therapy
Biopsy
Tumor Escape

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J. P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., Piha-Paul, S. A., Doi, T., Gao, B., Chung, H. C., Lopez-Martin, J., Bang, Y. J., Frommer, R. S., Shah, M., Ghori, R., Joe, A. K. & 2 others, Pruitt, S. K. & Diaz, L. A., Jan 1 2020, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38, 1, p. 1-10 10 p.

Research output: Contribution to journalArticle

Microsatellite Instability
DNA Mismatch Repair
Neoplasms
Therapeutics
Cholangiocarcinoma

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials

Hauschild, A., Ascierto, P. A., Schadendorf, D., Grob, J. J., Ribas, A., Kiecker, F., Dutriaux, C., Demidov, L. V., Lebbé, C., Rutkowski, P., Blank, C. U., Gutzmer, R., Millward, M., Kefford, R., Haas, T., D'Amelio, A., Gasal, E., Mookerjee, B. & Chapman, P. B., Jan 2020, In : European Journal of Cancer. 125, p. 114-120 7 p.

Research output: Contribution to journalArticle

Phase III Clinical Trials
Melanoma
Dacarbazine
Disease-Free Survival
dabrafenib

Nivolumab for the treatment of small cell lung cancer

Simeone, E., Grimaldi, A. M., Festino, L., Trojaniello, C., Vitale, M. G., Vanella, V., Curvietto, M. & Ascierto, P. A., 2020, In : Expert Review of Respiratory Medicine.

Research output: Contribution to journalArticle

Small Cell Lung Carcinoma
Drug Therapy
Immunotherapy
Clinical Trials
Therapeutics

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Ready, N. E., Ott, P. A., Hellmann, M. D., Zugazagoitia, J., Hann, C. L., de Braud, F., Antonia, S. J., Ascierto, P. A., Moreno, V., Atmaca, A., Salvagni, S., Taylor, M., Amin, A., Camidge, D. R., Horn, L., Calvo, E., Li, A., Lin, W. H., Callahan, M. K. & Spigel, D. R., 2020, (Accepted/In press) In : Journal of Thoracic Oncology.

Research output: Contribution to journalArticle

Open Access
Small Cell Lung Carcinoma
Survival
ipilimumab
nivolumab
Disease Progression
2019

Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway

Cristiani, C. M., Turdo, A., Ventura, V., Apuzzo, T., Capone, M., Madonna, G., Mallardo, D., Garofalo, C., Giovannone, E. D., Grimaldi, A. M., Tallerico, R., Marcenaro, E., Pesce, S., Zotto, G. D., Agosti, V., Costanzo, F. S., Gulletta, E., Rizzo, A., Moretta, A., Karre, K. & 3 others, Ascierto, P. A., Todaro, M. & Carbone, E., May 2019, In : Cancer immunology research. 7, 5, p. 841-852 12 p.

Research output: Contribution to journalArticle

Natural Killer Cells
Melanoma
Galectins
Neoplastic Stem Cells
T-Lymphocyte Subsets

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbe, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Hosein, F., de Pril, V., Kicinski, M., Suciu, S. & Testori, A., Sep 2019, In : European Journal of Cancer. 119, p. 1-10 10 p.

Research output: Contribution to journalArticle

Melanoma
Placebos
Survival
Neoplasm Metastasis
Recurrence

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J. J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbe, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Hosein, F., de Pril, V., Kicinski, M., Suciu, S. & Testori, A., Sep 1 2019, In : European Journal of Cancer. 119, p. 1-10 10 p.

Research output: Contribution to journalArticle

Melanoma
Placebos
Survival
Neoplasm Metastasis
Recurrence

Adverse events 2.0—Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology

Heinzerling, L., Ascierto, P. A., Dummer, R., Gogas, H., Grob, J. J., Lebbe, C., Long, G. V., McArthur, G., Moslehi, J. J., Neilan, T. G., Ribas, A., Robert, C., Schadendorf, D., Wolchok, J. D. & Hauschild, A., May 1 2019, In : European Journal of Cancer. 112, p. 29-31 3 p.

Research output: Contribution to journalLetter

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

Gogas, H. J., Flaherty, K. T., Dummer, R., Ascierto, P. A., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., Sileni, V. C., Dutriaux, C., de Groot, J. W. B., Yamazaki, N., Loquai, C., Gollerkeri, A., Pickard, M. D. & Robert, C., Sep 1 2019, In : European Journal of Cancer. 119, p. 97-106 10 p.

Research output: Contribution to journalArticle

Open Access
Cohort Studies
Mitogen-Activated Protein Kinase Kinases
Melanoma
encorafenib
MEK162

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

Gogas, H. J., Flaherty, K. T., Dummer, R., Ascierto, P. A., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., Sileni, V. C., Dutriaux, C., de Groot, J. W. B., Yamazaki, N., Loquai, C., Gollerkeri, A., Pickard, M. D. & Robert, C., Sep 2019, In : European Journal of Cancer. 119, p. 97-106 10 p.

Research output: Contribution to journalArticle

Cohort Studies
Mitogen-Activated Protein Kinase Kinases
Melanoma
encorafenib
MEK162

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable

Cortellini, A., Bersanelli, M., Buti, S., Cannita, K., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Michiara, M., Di Marino, P., Tinari, N., De Tursi, M., Zoratto, F., Veltri, E., Marconcini, R., Malorgio, F., Russano, M., Anesi, C., Zeppola, T., Filetti, M. & 25 others, Marchetti, P., Botticelli, A., Antonini Cappellini, G. C., De Galitiis, F., Vitale, M. G., Rastelli, F., Pergolesi, F., Berardi, R., Rinaldi, S., Tudini, M., Silva, R. R., Pireddu, A., Atzori, F., Chiari, R., Ricciuti, B., De Giglio, A., Iacono, D., Gelibter, A., Occhipinti, M. A., Parisi, A., Porzio, G., Fargnoli, M. C., Ascierto, P. A., Ficorella, C. & Natoli, C., Feb 27 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 57.

Research output: Contribution to journalArticle

Open Access
Multicenter Studies
Body Mass Index
Neoplasms
Thinness
Renal Cell Carcinoma

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 others, Rutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
PLX4032

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 others, Rutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 1 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
PLX4032

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 others, Rutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients

Weide, B., Eigentler, T., Catania, C., Ascierto, P. A., Cascinu, S., Becker, J. C., Hauschild, A., Romanini, A., Danielli, R., Dummer, R., Trefzer, U., Elia, G., Neri, D. & Garbe, C., 2019, In : Cancer Immunology, Immunotherapy.

Research output: Contribution to journalArticle

Dacarbazine
Melanoma
Interleukin-2
Phase II Clinical Trials
Fibronectins

Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma

Harder, N., Schönmeyer, R., Nekolla, K., Meier, A., Brieu, N., Vanegas, C., Madonna, G., Capone, M., Botti, G., Ascierto, P. A. & Schmidt, G., May 15 2019, In : Sci. Rep.. 9, 1, p. 7449

Research output: Contribution to journalArticle

Routine Diagnostic Tests
Melanoma
Tumor-Infiltrating Lymphocytes
Decision Trees
Precision Medicine

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

Van Herpen, C. M. L., Agarwala, S. S., Hauschild, A., Berking, C., Thaddeus Beck, J., Schadendorf, D., Jansen, R., Queirolo, P., Ascierto, P. A., Blank, C. U., Heinrich, M. C., Pal, R. R., Derti, A., Antona, V., Nauwelaerts, H., Zubel, A. & Dummer, R., Mar 1 2019, In : Oncotarget. 10, 19, p. 1850-1859 10 p.

Research output: Contribution to journalArticle

Melanoma
Biomarkers
Mitogen-Activated Protein Kinases
Mitogen-Activated Protein Kinase Kinases
Mutation

BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas

Colombino, M., Paliogiannis, P., Cossu, A., De Re, V., Miolo, G., Botti, G., Scognamiglio, G., Ascierto, P. A., Santeufemia, D. A., Fraggetta, F., Manca, A., Sini, M. C., Casula, M., Palomba, G., Pisano, M., Doneddu, V., Lissia, A., Fedeli, M. A. & Palmieri, G., Oct 1 2019, In : Journal of Clinical Medicine. 8, 10, 13 p., 1577.

Research output: Contribution to journalArticle

Melanoma
Phosphotransferases
Mutation
Genes
Immune Tolerance

Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab

Quagliariello, V., Passariello, M., Coppola, C., Rea, D., Barbieri, A., Scherillo, M., Monti, M. G., Iaffaioli, R. V., De Laurentiis, M., Ascierto, P. A., Botti, G., De Lorenzo, C. & Maurea, N., 2019, In : International Journal of Cardiology.

Research output: Contribution to journalArticle

NF-kappa B
Leukotriene B4
Cardiac Myocytes
Interleukins
Immunotherapy

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

Antonia, S. J., Balmanoukian, A., Brahmer, J., Ou, S. H. I., Hellmann, M. D., Kim, S. W., Ahn, M. J., Kim, D. W., Gutierrez, M., Liu, S. V., Schöffski, P., Jäger, D., Jamal, R., Jerusalem, G., Lutzky, J., Nemunaitis, J., Calabrò, L., Weiss, J., Gadgeel, S., Bhosle, J. & 11 others, Ascierto, P. A., Rebelatto, M. C., Narwal, R., Liang, M., Xiao, F., Antal, J., Abdullah, S., Angra, N., Gupta, A. K., Khleif, S. N. & Segal, N. H., Oct 1 2019, In : Journal of Thoracic Oncology. 14, 10, p. 1794-1806 13 p.

Research output: Contribution to journalArticle

Open Access
Cell Death
Ligands
Safety
Disease-Free Survival
Pneumonia

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Cortellini, A., Buti, S., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Bersanelli, M., Michiara, M., Grassadonia, A., Brocco, D., Tinari, N., De Tursi, M., Zoratto, F., Veltri, E., Marconcini, R., Malorgio, F., Garufi, C., Russano, M., Anesi, C., Zeppola, T. & 25 others, Filetti, M., Marchetti, P., Botticelli, A., Antonini Cappellini, G. C., De Galitiis, F., Vitale, M. G., Sabbatini, R., Bracarda, S., Berardi, R., Rinaldi, S., Tudini, M., Silva, R. R., Pireddu, A., Atzori, F., Chiari, R., Ricciuti, B., Iacono, D., Migliorino, M. R., Rossi, A., Porzio, G., Cannita, K., Ciciarelli, V., Fargnoli, M. C., Ascierto, P. A. & Ficorella, C., 2019, In : Oncologist.

Research output: Contribution to journalArticle

Preexisting Condition Coverage
Immunotherapy
Autoimmune Diseases
Neoplasms
Incidence

Correction: New paradigm for stage III melanoma: From surgery to adjuvant treatment (Journal of Translational Medicine (2019) 17 (266) DOI: 10.1186/s12967-019-2012-2)

Ascierto, P. A., Borgognoni, L., Botti, G., Guida, M., Marchetti, P., Mocellin, S., Muto, P., Palmieri, G., Patuzzo, R., Quaglino, P., Stanganelli, I. & Caracò, C., Sep 18 2019, In : Journal of Translational Medicine. 17, 1, 315.

Research output: Contribution to journalComment/debate

Open Access
Translational Medical Research
Fluorouracil
Surgery
Medicine
Publications
Biological Factors
Antineoplastic Agents
clinical trials
Clinical Trials
Costs and Cost Analysis

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

ESMO Guidelines Committee, Dec 1 2019, In : Annals of oncology : official journal of the European Society for Medical Oncology. 30, 12, p. 1884-1901 18 p.

Research output: Contribution to journalArticle

Open Access

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., Svane, I. M., Lotem, M., Bar-Sela, G., Couture, F., Mookerjee, B., Ghori, R., Ibrahim, N., Moreno, B. H. & Ribas, A., Jun 1 2019, In : Nature Medicine. 25, 6, p. 941-946 6 p.

Research output: Contribution to journalLetter

Melanoma
Placebos
Blocking Antibodies
Mitogen-Activated Protein Kinase Kinases
Transaminases

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., Svane, I. M., Lotem, M., Bar-Sela, G., Couture, F., Mookerjee, B., Ghori, R., Ibrahim, N., Moreno, B. H. & Ribas, A., Jun 1 2019, In : Nature Medicine. 25, 6, p. 941-946 6 p.

Research output: Contribution to journalLetter

Melanoma
Placebos
Blocking Antibodies
Mitogen-Activated Protein Kinase Kinases
Transaminases

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice

Cortellini, A., Vitale, M. G., De Galitiis, F., Di Pietro, F. R., Berardi, R., Torniai, M., De Tursi, M., Grassadonia, A., Di Marino, P., Santini, D., Zeppola, T., Anesi, C., Gelibter, A., Occhipinti, M. A., Botticelli, A., Marchetti, P., Rastelli, F., Pergolesi, F., Tudini, M., Silva, R. R. & 5 others, Mallardo, D., Vanella, V., Ficorella, C., Porzio, G. & Ascierto, P. A., Nov 15 2019, In : Journal of Translational Medicine. 17, 1, 376.

Research output: Contribution to journalArticle

Corrosion inhibitors
Fatigue
Fatigue of materials
Neoplasms
Renal Cell Carcinoma

Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation–positive metastatic melanoma treated with vemurafenib ± cobimetinib

Lewis, K., Hauschild, A., Larkin, J., Ribas, A., Flaherty, K. T., McArthur, G. A., Dréno, B., McKenna, E., Zhu, Q., Mun, Y. & Ascierto, P. A., Jul 1 2019, In : European Journal of Cancer. 116, p. 45-55 11 p.

Research output: Contribution to journalArticle

Reducing Agents
Melanoma
Acids
Survival
GDC-0973

Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations

Trojaniello, C., Festino, L., Vanella, V. & Ascierto, P. A., Mar 4 2019, In : Expert Review of Clinical Pharmacology. 12, 3, p. 259-266 8 p.

Research output: Contribution to journalReview article

Melanoma
Mitogen-Activated Protein Kinase Kinases
Mutation
Disease-Free Survival
Disease Resistance

Enzyme activity of circulating CD73 in human serum

Morello, S., Turiello, R., Madonna, G., Pinto, A., Ascierto, P. A. & Capone, M., 2019, In : Methods in Enzymology. 629, p. 257-267 11 p.

Research output: Contribution to journalArticle

Enzyme activity
Adenosine
Enzymes
Serum
Neoplasms

ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin

Ruggiero, C. F., Malpicci, D., Fattore, L., Madonna, G., Vanella, V., Mallardo, D., Liguoro, D., Salvati, V., Capone, M., Bedogni, B., Ascierto, P. A., Mancini, R. & Ciliberto, G., Sep 25 2019, In : Cancers. 11, 10

Research output: Contribution to journalArticle

Neuregulins
Circulating Neoplastic Cells
Cell- and Tissue-Based Therapy
Melanoma
Phosphorylation

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

Lebbé, C., Meyer, N., Mortier, L., Marquez-Rodas, I., Robert, C., Rutkowski, P., Menzies, A. M., Eigentler, T., Ascierto, P. A., Smylie, M., Schadendorf, D., Ajaz, M., Svane, I. M., Gonzalez, R., Rollin, L., Lord-Bessen, J., Saci, A., Grigoryeva, E. & Pigozzo, J., Apr 10 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 11, p. 867-875 9 p.

Research output: Contribution to journalArticle

Melanoma
Disease-Free Survival
Incidence
Survival
Therapeutics

Five-year survival with combined nivolumab and ipilimumab in advanced melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Hogg, D., Hill, A., Márquez-Rodas, I., Haanen, J., Guidoboni, M., Maio, M., Schöffski, P., Carlino, M. S. & 11 others, Lebbé, C., McArthur, G., Ascierto, P. A., Daniels, G. A., Long, G. V., Bastholt, L., Rizzo, J. I., Balogh, A., Moshyk, A., Hodi, F. S. & Wolchok, J. D., 2019, In : New England Journal of Medicine. 381, 16, p. 1535-1546 12 p.

Research output: Contribution to journalArticle

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Hogg, D., Hill, A., Márquez-Rodas, I., Haanen, J., Guidoboni, M., Maio, M., Schöffski, P., Carlino, M. S. & 11 others, Lebbé, C., McArthur, G., Ascierto, P. A., Daniels, G. A., Long, G. V., Bastholt, L., Rizzo, J. I., Balogh, A., Moshyk, A., Hodi, F. S. & Wolchok, J. D., Oct 17 2019, In : New England Journal of Medicine. 381, 16, p. 1535-1546 12 p.

Research output: Contribution to journalArticle

Melanoma
Survival
ipilimumab
nivolumab
Disease-Free Survival

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Hogg, D., Hill, A., Márquez-Rodas, I., Haanen, J., Guidoboni, M., Maio, M., Schöffski, P., Carlino, M. S. & 11 others, Lebbé, C., McArthur, G., Ascierto, P. A., Daniels, G. A., Long, G. V., Bastholt, L., Rizzo, J. I., Balogh, A., Moshyk, A., Hodi, F. S. & Wolchok, J. D., Oct 17 2019, In : The New England journal of medicine. 381, 16, p. 1535-1546 12 p.

Research output: Contribution to journalArticle

Melanoma
Survival
ipilimumab
nivolumab
Disease-Free Survival

Germline and somatic mutations in patients with multiple primary melanomas: A next generation sequencing study

Casula, M., Paliogiannis, P., Ayala, F., De Giorgi, V., Stanganelli, I., Mandalà, M., Colombino, M., Manca, A., Sini, M. C., Caracò, C., Ascierto, P. A., Satta, R. R., Dedola, M. F., Denti, S., Fedeli, M. A., Montesu, M. A., Profili, S., Scotto, T., Sini, G., Tanda, F. & 9 others, Lissia, A., Cossu, A., Palmieri, G., Ghiorzo, P., Queirolo, P., Quaglino, P., Botti, G., Sileni, V. C. & Di Giacomo, A. M., Aug 5 2019, In : BMC Cancer. 19, 1, 772.

Research output: Contribution to journalArticle

Open Access
Germ-Line Mutation
Melanoma
Mutation
Italy
Population

Health-related quality of life in patients with fully resected BRAFV600 mutation–positive melanoma receiving adjuvant vemurafenib

the BRIM8 Investigators, Dec 2019, In : European Journal of Cancer. 123, p. 155-161 7 p.

Research output: Contribution to journalArticle

Melanoma
Quality of Life
Health Status
Therapeutics
PLX4032

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

Lewis, K. D., Larkin, J., Ribas, A., Flaherty, K. T., McArthur, G. A., Ascierto, P. A., Dréno, B., Yan, Y., Wongchenko, M., McKenna, E., Zhu, Q., Mun, Y. & Hauschild, A., Jan 1 2019, In : British Journal of Cancer.

Research output: Contribution to journalArticle

Open Access
Survival
Disease-Free Survival
Melanoma
Genes
GDC-0973

Mutational concordance between primary and metastatic melanoma: A next-generation sequencing approach

Manca, A., Paliogiannis, P., Colombino, M., Casula, M., Lissia, A., Botti, G., Caracò, C., Ascierto, P. A., Sini, M. C., Palomba, G., Pisano, M., Dedola, M. F., Fedeli, M. A., Montesu, M. A., Rubino, C., Satta, R., Scotto, T., Sini, G., Maio, M., Massi, D. & 10 others, Anichini, A., Pfeffer, U., Doneddu, V., Cossu, A., Palmieri, G., Ghiorzo, P., Queirolo, P., Quaglino, P., Sileni, V. C. & Di Giacomo, A. M., 2019, In : Journal of Translational Medicine. 17, 1

Research output: Contribution to journalArticle

Melanoma
Genes
Tissue
Mutation
Literature

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

International Neoadjuvant Melanoma Consortium., Jul 1 2019, In : The Lancet Oncology. 20, 7, p. e378-e389

Research output: Contribution to journalReview article

Neoadjuvant Therapy
Melanoma
Translational Medical Research
Biomarkers
Anus Neoplasms

New paradigm for stage III melanoma: from surgery to adjuvant treatment

Ascierto, P. A., Borgognoni, L., Botti, G., Guida, M., Marchetti, P., Mocellin, S., Muto, P., Palmieri, G., Patuzzo, R., Quaglino, P., Stanganelli, I. & Caracò, C., Aug 14 2019, In : Journal of Translational Medicine. 17, 1, p. 266

Research output: Contribution to journalReview article

Dissection
Lymph Node Excision
Surgery
Melanoma
Therapeutics

New paradigm for stage III melanoma: from surgery to adjuvant treatment: Journal of Translational Medicine

Ascierto, P. A., Borgognoni, L., Botti, G., Guida, M., Marchetti, P., Mocellin, S., Muto, P., Palmieri, G., Patuzzo, R., Quaglino, P., Stanganelli, I. & Caracò, C., 2019, In : Journal of Translational Medicine. 17, 1

Research output: Contribution to journalArticle

Dissection
Translational Medical Research
Lymph Node Excision
Surgery
Medicine

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

Sharma, P., Siefker-Radtke, A., de Braud, F., Basso, U., Calvo, E., Bono, P., Morse, M. A., Ascierto, P. A., Lopez-Martin, J., Brossart, P., Rohrberg, K., Mellado, B., Fischer, B. S., Meadows-Shropshire, S., Abdel Saci, Callahan, M. K. & Rosenberg, J., Jul 1 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 19, p. 1608-1616 9 p.

Research output: Contribution to journalArticle

Carcinoma
Platinum
Immunotherapy
Multicenter Studies
Disease Progression

Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results

Sharma, P., Siefker-Radtke, A., de Braud, F., Basso, U., Calvo, E., Bono, P., Morse, M. A., Ascierto, P. A., Lopez-Martin, J., Brossart, P., Rohrberg, K., Mellado, B., Fischer, B. S., Meadows-Shropshire, S., Saci, A., Callahan, M. K. & Rosenberg, J., 2019, In : Journal of Clinical Oncology. 37, 19, p. 1608-1616 9 p.

Research output: Contribution to journalArticle

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)

Ascierto, P. A., Bifulco, C., Buonaguro, L., Emens, L. A., Ferris, R. L., Fox, B. A., Delgoffe, G. M., Galon, J., Gridelli, C., Merlano, M., Nathan, P., Odunsi, K., Okada, H., Paulos, C. M., Pignata, S., Schalper, K. A., Spranger, S., Tortora, G., Zarour, H., Butterfield, L. H. & 1 others, Puzanov, I., Nov 29 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 1 p.

Research output: Contribution to journalReview article

Immunotherapy
Italy
Neoplasms
Tumor Microenvironment
Skin Neoplasms

Perspectives in melanoma: Meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)

Ascierto, P. A., Agarwala, S. S., Botti, G., Budillon, A., Davies, M. A., Dummer, R., Ernstoff, M., Ferrone, S., Formenti, S., Gajewski, T. F., Garbe, C., Hamid, O., Lo, R. S., Luke, J. J., Michielin, O., Palmieri, G., Zitvogel, L., Marincola, F. M., Masucci, G., Caracò, C. & 2 others, Thurin, M. & Puzanov, I., Jul 22 2019, In : Journal of Translational Medicine. 17, 1, 234.

Research output: Contribution to journalArticle

Open Access
Italy
Tumors
Melanoma
Biomarkers
Neoplasms

Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis

Ascierto, P. A., Bifulco, C., Palmieri, G., Peters, S. & Sidiropoulos, N., Sep 1 2019, In : Journal of Molecular Diagnostics. 21, 5, p. 756-767 12 p.

Research output: Contribution to journalReview article

Open Access
Neoplasms
Biomarkers
Precision Medicine
Routine Diagnostic Tests
Nucleic Acids

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. JM. & 12 others, Grob, J. J., Gutzmer, R., Jamal, R., Lorigan, P. C., Lupinacci, R., Krepler, C., Ibrahim, N., Kicinski, M., Marreaud, S., van Akkooi, A. C., Suciu, S. & Robert, C., Jul 1 2019, In : European Journal of Cancer. 116, p. 148-157 10 p.

Research output: Contribution to journalArticle

Melanoma
Placebos
Recurrence
Neoplasms
Survival